BioMarin Pharmaceutical Inc.
BMRN
$58.58
$0.510.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 825.41M | 745.15M | 747.31M | 745.74M | 712.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 825.41M | 745.15M | 747.31M | 745.74M | 712.03M |
| Cost of Revenue | 311.40M | 310.29M | 136.14M | 188.46M | 314.25M |
| Gross Profit | 514.01M | 434.86M | 611.17M | 557.28M | 397.78M |
| SG&A Expenses | 232.28M | 206.12M | 170.78M | 253.48M | 263.03M |
| Depreciation & Amortization | 4.85M | 4.85M | 9.65M | 5.01M | 14.30M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 548.52M | 521.25M | 490.08M | 631.85M | 591.58M |
| Operating Income | 276.89M | 223.89M | 257.24M | 113.89M | 120.45M |
| Income Before Tax | 297.87M | 238.09M | 169.64M | 134.44M | 132.14M |
| Income Tax Expenses | 57.34M | 52.40M | 44.70M | 28.36M | 24.96M |
| Earnings from Continuing Operations | 240.53M | 185.69M | 124.94M | 106.08M | 107.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 240.53M | 185.69M | 124.94M | 106.08M | 107.17M |
| EBIT | 276.89M | 223.89M | 257.24M | 113.89M | 120.45M |
| EBITDA | 295.45M | 245.96M | 280.84M | 132.90M | 146.92M |
| EPS Basic | 1.25 | 0.97 | 0.66 | 0.56 | 0.56 |
| Normalized Basic EPS | 0.97 | 0.78 | 0.87 | 0.44 | 0.43 |
| EPS Diluted | 1.23 | 0.95 | 0.64 | 0.55 | 0.55 |
| Normalized Diluted EPS | 0.94 | 0.76 | 0.84 | 0.43 | 0.41 |
| Average Basic Shares Outstanding | 191.91M | 190.97M | 190.69M | 190.43M | 190.11M |
| Average Diluted Shares Outstanding | 197.09M | 196.47M | 196.58M | 197.15M | 200.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |